Bedside Snapshot
- Use It For
- Cardiogenic shock or low-output heart failure; low output after cardiac surgery; septic shock with cardiac dysfunction and persistent hypoperfusion (with norepinephrine)
- Adult Dose
- Cardiogenic shock or low output: start 0.5–1 mcg/kg/min, usual 2–10 (max 40, rare)
- Differs from FDA label: premix 2–20 mcg/kg/min
- Septic: 2–20 mcg/kg/min, premix label only (SSC 2026: no dose); stop if no perfusion gain
- Pediatric Dose
- Not established in children; specialist use only, including neonates
- Onset / Duration
- IV infusion: onset 1–2 min, peak up to 10 min / effect gone about 10 min after stopping (half-life about 2 min)
- Do Not Give / Hold If
- Hypertrophic cardiomyopathy with outflow obstruction; dobutamine hypersensitivity. Reduce or hold per protocol for marked tachycardia (e.g. HR up 30 bpm or more), new AF or ectopy, ischemia, or falling BP
- Watch For
- Tachycardia and AF with rapid response (ECG); PVCs or VT (monitor); hypotension from vasodilation (arterial line); angina or ST changes; low K⁺
- Reversal / Rescue
- No specific reversal: stop or reduce (half-life about 2 min). Hypotension: fluid if underfilled plus a vasopressor. Severe VT: ACLS/PALS (label: propranolol or lidocaine; β-blocker with great caution in low output)
- Must Remember
- Inotrope, not pressor, and DOBUTamine is not DOPamine: confirm drug, 1, 2 or 4 mg/mL bag, dosing weight and mcg/kg/min on the pump. Low MAP needs norepinephrine too
Indications
Emergency & Prehospital
- Cardiogenic shock with low cardiac output: an inotrope to restore perfusion, including after return of spontaneous circulation (ROSC). Run it with norepinephrine when MAP is low
ED / ICU / Transport
- Acute decompensated heart failure with low output and hypoperfusion: the cause is depressed contractility. FDA-labeled for short-term use.
- Low cardiac output after cardiac surgery: FDA-labeled short-term use
- Septic shock with cardiac dysfunction: hypoperfusion persists despite adequate volume and MAP. Surviving Sepsis Campaign (SSC) 2026 suggests adding dobutamine to norepinephrine, or using epinephrine alone. Inotropes go on top of vasopressors. They do not replace them (off-label)
- Pediatric low-output states: myocarditis, cardiomyopathy and after cardiac surgery. In septic shock with cardiac dysfunction, specialist use only (see Pediatric Shock)
Other Uses
- Stage D (advanced) heart failure: run it as a continuous infusion. It bridges to transplant or mechanical circulatory support, or it is palliation for patients who are not candidates
- Pharmacologic stress echocardiography: a diagnostic stress test in the echo lab, run under its own protocol (off-label)
Not a vasopressor and not an arrest drug: It raises cardiac output, but vasodilation can still pull blood pressure down. It has no role during CPR. It does not treat hypotension on its own.
Dosing & Administration
The lead dose follows the 2025 ACC cardiogenic shock guidance. Where the FDA label differs, each row says so.
Available Forms
- Premixed bags in 5% dextrose (D5W), common in ED, ICU and transport: 1 mg/mL (250 mg/250 mL), 2 mg/mL (500 mg/250 mL) and 4 mg/mL (1,000 mg/250 mL). Contain a sulfite stabilizer (sodium metabisulfite or bisulfite), as does the vial
- Concentrate vial: 12.5 mg/mL in 20 mL (250 mg) single-dose vial; must be diluted. Contains sodium metabisulfite
High-Alert Medication: Three ways this goes wrong. DOBUTamine and DOPamine get mixed up. The wrong premix gets picked in the pump library (1, 2 and 4 mg/mL bags give a 2- to 4-fold error). mcg/kg/min gets read as mcg/min. Check the drug, concentration, dosing weight and pump rate yourself. Do it at start, at every bag change and at handoff.
Adult Dosing
| Indication | Dose & Route | Repeat / Max | Notes |
|---|---|---|---|
| Low-output heart failure, cardiogenic shock or low output after cardiac surgery | Start 0.5–1; 2–10 mcg/kg/min IV infusion (usual range); titrate every few minutes | Max 40 mcg/kg/min (rarely needed); use the lowest dose that restores perfusion, for the shortest time | High-alert ACC 2025 cardiogenic shock guidance gives a usual range of 2–10 mcg/kg/min. Differs from FDA label: premix label usual range 2–20 mcg/kg/min, rarely up to 40; vial label usual range 2.5–15. Low MAP: run with norepinephrine. Titrate to perfusion, heart rate, ectopy and, when available, cardiac output and wedge pressure |
| Septic shock with cardiac dysfunction (added to norepinephrine) | Start at the low end of the range; usual range 2–20 mcg/kg/min IV infusion (premix label range; SSC 2026 gives no dose) | Usual max 20 mcg/kg/min; stop if hypoperfusion does not improve or adverse effects appear | High-alert Only after volume and MAP are adequate, and in addition to a vasopressor, not instead of one. SSC 2026 gives no dose and found too little data to choose dobutamine over milrinone |
| Stage D heart failure (bridge or palliation) | Continuous IV infusion at the lowest effective dose, set by the advanced heart failure team | Specialist-directed; no fixed max | High-alert Long-term cyclic-AMP inotropes are linked to more hospitalization and death; use only as a bridge or for palliation |
Dosing weight: The label doses by body weight and says nothing about obesity. Pick your institution's convention, actual or adjusted weight, and use it every time. Say which one you used at handoff.
Pediatric Dosing
| Indication | Dose (per kg) & Route | Max Single / Max Total | Notes |
|---|---|---|---|
| Low cardiac output (myocarditis, cardiomyopathy, after cardiac surgery) | Specialist use only | — | High-alert Premix labels: raises output and blood pressure at every pediatric age. The vial label states pediatric safety and effectiveness have not been studied. Not established in children; specialist use only. No labeled pediatric dose |
| Septic shock with cardiac dysfunction despite fluids and a vasopressor (specialist use only) | Specialist use only: added to epinephrine or norepinephrine; not established in children | — | High-alert SSC 2026 (children) found too little evidence to recommend for or against adding an inodilator such as dobutamine, and states no preference between epinephrine and norepinephrine first-line. It suggests targeting ScvO₂ 70% or higher when central venous access is available (conditional, very low certainty). Not established in children; specialist use only |
| Neonates | Specialist use only | — | In premature neonates it was less effective than dopamine at raising blood pressure without causing undue tachycardia, and added no benefit in infants already on optimal dopamine (label). Neonatal intensivist and pharmacy dosing only |
Pediatric doses come from AHA/AAP 2025 when it gives a number. If it doesn't, we go to the NASEMSO National Model EMS Clinical Guidelines v3.0 (2022), then the US label. Where none gives a dose, none is shown. The label has no pediatric dose. AHA 2025 PALS (Part 8) calls dobutamine a reasonable inotrope for children with cardiogenic shock, but gives no dose. Premixed bags may not suit children under 30 kg (label). Run your weight-based dosing checks.
Continuous Infusion
| Setting | Example Concentration | Start | Titrate | Usual Range / Max |
|---|---|---|---|---|
| Adult, premixed bag | 1 mg/mL (1,000 mcg/mL), example (institution-specific); 2 or 4 mg/mL for fluid restriction | 0.5–1 mcg/kg/min | Every few minutes to perfusion and heart rate | 2–10 mcg/kg/min usual (label to 20); max 40 mcg/kg/min |
| Adult, compounded from vial | 250 mg vial diluted to at least 50 mL (no more than 5 mg/mL), example (institution-specific) | 0.5–1 mcg/kg/min | Every few minutes to perfusion and heart rate | 2–10 mcg/kg/min usual (label to 20); max 40 mcg/kg/min |
Pump rate (weight-based)
mL/hr = dose (mcg/kg/min) × weight (kg) × 60 ÷ concentration (mcg/mL). Example: 5 mcg/kg/min × 80 kg × 60 ÷ 1,000 mcg/mL = 24 mL/hr
Preparation & Administration
- Dilution: use a premixed bag when available. Vial: dilute to at least 50 mL in D5W, 0.9% NaCl, lactated Ringer's or sodium lactate; use within 24 hr.
- IO: Both labels describe IV use only. The vial says for intravenous use only, and the premix says administered intravenously. An IO infusion when IV access fails is off-label.
- Pump requirement: Smart pump, with a drug library, on a dedicated line or lumen. Never IV push or bolus.
- Line: Use a large peripheral vein or a central line. Check the site often. Phlebitis happens, and isolated cases of skin necrosis after infiltration have been reported.
- Premixed bags: Add no other drugs. Don't connect bags in series. A pink tint is slight oxidation, and it does not cost significant potency.
- Weaning: Taper as perfusion improves. Watch blood pressure, urine output and lactate while you do.
Contraindications & Precautions
Contraindications
- Idiopathic hypertrophic subaortic stenosis (hypertrophic cardiomyopathy with outflow obstruction): It can worsen the dynamic obstruction.
- Prior hypersensitivity to dobutamine or a product component.
Precautions
- Atrial fibrillation: It speeds AV conduction. The label advises digitalis first in AF with rapid response. Control the rate per protocol.
- Hypovolemia: Correct the volume first. Dobutamine can drop blood pressure in an underfilled patient.
- Severe aortic stenosis or other fixed obstruction: output may not improve.
- Acute myocardial infarction or active ischemia: Safety is not established. It raises myocardial oxygen demand.
- Sulfite sensitivity or asthma: Bisulfite or metabisulfite can trigger allergic-type reactions, anaphylaxis included.
- Pre-existing hypertension: The pressor response can be exaggerated, so the risk is higher.
- Diabetes: Premixed bags run in D5W, so they add a glucose load. Monitor glucose.
- Corn allergy: The dextrose in premixed bags comes from corn. With a known corn allergy, consider that.
Hold / Reassess If
These heart rate and blood pressure numbers are practical triggers, not label hold criteria. The label trials saw about 10% of patients with a heart rate rise of 30 bpm or more, and about 7.5% with a systolic rise of 50 mmHg or more. Follow local protocol.
- Marked tachycardia (e.g. heart rate up 30 bpm or more), or new AF with rapid response: reduce the dose. Treat the rhythm.
- New or increasing PVCs, or ventricular tachycardia: reduce or stop. Check K⁺ and Mg²⁺.
- Systolic BP falls or MAP drops below goal: Reassess volume. Add or increase a vasopressor. Reduce dobutamine.
- Marked hypertension (e.g. systolic BP up 50 mmHg or more), chest pain or ischemic ST changes: reduce or stop.
- No improvement in perfusion (lactate, urine output, mentation) after a trial. Stop rather than escalate.
Dynamic outflow obstruction: Hypertrophic cardiomyopathy or a small hyperdynamic ventricle sets this up. Dobutamine can create outflow obstruction, and the pressure falls with it. Stop it. Give fluid. Use a pure vasoconstrictor such as phenylephrine, and consider a short-acting β-blocker (e.g. esmolol) per protocol. Avoid further inotropes and vasodilators.
Adverse Effects & Toxicity
Common
- Heart rate up 5–15 bpm and systolic BP up 10–20 mmHg in most patients (dose-related)
- Heart rate up 30 bpm or more in about 10%; systolic BP up 50 mmHg or more in about 7.5%
- More PVCs in about 5%
- Nausea, headache, angina or nonspecific chest pain, palpitations, dyspnea (1–3% each)
- Mild fall in serum K⁺; phlebitis at the infusion site
Rare: these are isolated cases, reported on the vial label: thrombocytopenia, and skin necrosis at the infusion site.
Serious / Life-Threatening
| Effect | Recognition | Management |
|---|---|---|
| Tachyarrhythmias | AF with rapid response, runs of PVCs, ventricular tachycardia (rare) on the monitor | Reduce or stop; correct K⁺ and Mg²⁺; rate control or ACLS as needed |
| Myocardial ischemia | Angina, ST changes, troponin rise | Reduce or stop; treat ischemia |
| Precipitous hypotension | MAP falls soon after starting or increasing the dose | Reduce or stop; give fluid if underfilled; add a vasopressor; look for outflow obstruction |
| Hypersensitivity and sulfite reactions | Rash, fever, eosinophilia, bronchospasm, anaphylaxis | Stop; treat anaphylaxis; switch inotrope |
| Stress (Takotsubo) cardiomyopathy | New wall-motion abnormality, reported mainly with stress testing | Stop; supportive care; echocardiography |
Overdose & Toxicity Management
- Signs: excess β stimulation: tremor, anxiety, nausea, palpitations, headache, dyspnea, angina, hypertension or vasodilatory hypotension, tachyarrhythmias up to ventricular fibrillation.
- Immediate: stop the infusion (half-life about 2 min); secure airway, oxygenation and ventilation; hypertension usually settles with dose reduction.
- Antidote: No specific antidote. Treat severe ventricular arrhythmias per ACLS/PALS. The label names propranolol or lidocaine. Use β-blockers only with great caution in low-output states. Per the label, forced diuresis, peritoneal or hemodialysis, and charcoal hemoperfusion have not been established as beneficial.
Monitoring
| Parameter | When / How Often | Target / Act If |
|---|---|---|
| Clinical: ECG rhythm, rate and ST segments | Continuous | Heart rate up 30 bpm or more, new AF or more ectopy: reduce. Chest pain or ST change: reduce or stop; 12-lead ECG and troponin |
| Clinical: blood pressure | Continuous arterial line in shock; otherwise every 5 min while titrating | MAP below goal (65 mmHg in septic shock; SSC 2026 suggests 60–65 mmHg at age 65 or older): add or raise a vasopressor, reassess volume. Systolic up 50 mmHg or more: reduce |
| Clinical: perfusion | Hourly: mentation, skin and capillary refill, urine output | Urine <0.5 mL/kg/hr or capillary refill >3 sec despite the dose: reassess output and volume. Hypoperfusion despite drug therapy: early shock-team consultation, transfer to a Level 1 shock center and temporary mechanical circulatory support |
| Clinical: hemodynamics | Cardiac output or index and wedge pressure when a pulmonary artery catheter or other monitor is in place (see Hemodynamic Monitoring) | Cardiac index not rising, or heart rate rising without a gain in stroke volume: reconsider the drug |
| Laboratory: lactate | Baseline and every 2–4 hr while elevated | Not falling after a trial: inotrope not helping; stop or change strategy |
| Laboratory: creatinine and renal function | Baseline and at least daily | Rising despite therapy: output still inadequate; reassess. Worsening renal function favors dobutamine over renally cleared milrinone |
| Laboratory: potassium and magnesium | Baseline and at least daily, more often with arrhythmias or diuretics | Low K⁺ or Mg²⁺: replace (lowers arrhythmia risk) |
| Infusion safety: site and pump | Site at least hourly; concentration and weight at every bag change and handoff | Swelling, pain or blanching: stop, move the line; pump library concentration must match the bag |
Interactions & Compatibility
Clinically Significant Interactions
| Drug / Class | Effect | What To Do |
|---|---|---|
| β-blockers (metoprolol, carvedilol, esmolol) | Blunted inotropic response; vascular resistance may rise from unopposed α effect | Expect higher dose needs; consider milrinone, which works independently of β-receptors |
| COMT inhibitors (entacapone, opicapone, tolcapone) | Reduced dobutamine metabolism; may raise heart rate, cause arrhythmias and change blood pressure (premix label) | Start at the low end, titrate cautiously, monitor ECG and blood pressure closely |
| Nitroprusside | Higher cardiac output and usually lower wedge pressure than either drug alone | Intended combination in low-output, high-afterload states; watch blood pressure closely |
| Other catecholamines and inotropes (epinephrine, dopamine, isoproterenol) | Additive tachycardia, arrhythmias and myocardial oxygen demand | Reassess whether each agent still adds benefit; titrate one at a time |
| K⁺-lowering drugs (loop diuretics, β₂-agonists, insulin) | Additive hypokalemia and arrhythmia risk | Monitor and replace K⁺ and Mg²⁺ |
IV Compatibility
- Diluents: D5W, 0.9% NaCl, lactated Ringer's or sodium lactate (vial label). Premixed bags are in D5W.
- Avoid: Sodium bicarbonate and other strongly alkaline solutions inactivate dobutamine. Don't use diluents containing both sodium bisulfite and ethanol. Don't mix other drugs into the same bag. Don't run it through the same set as blood.
- Dedicated line or lumen: no boluses or flushes through the dobutamine line.
- Verify with an institutional compatibility resource.
Special Populations
- Pediatrics: Used for low-output states. In septic shock it is specialist use only. SSC 2026 (children) found too little evidence to recommend for or against adding an inodilator such as dobutamine. The same guideline suggests a ScvO₂ target of 70% or higher when central venous access is available (conditional, very low certainty). Premix labels report higher output and blood pressure at every pediatric age. The vial label says pediatric safety and effectiveness have not been studied. See the Pediatric Dosing table.
- Neonates: In premature neonates it was less effective than dopamine at raising blood pressure without causing undue tachycardia. In infants already on optimal dopamine, it added no benefit (label). Neonatal specialist use only.
- Pregnancy: Rat studies at up to the usual human dose, and rabbit studies at up to twice that dose, showed no fetal harm. There are no adequate human studies, so use it only if clearly needed. Untreated cardiogenic shock harms mother and fetus. Do not withhold indicated therapy.
- Lactation: There are no data on transfer into human milk. The vial label advises stopping breastfeeding for the duration of treatment.
- Older Adults: Too few older patients were studied to show a different response. Start at the low end of the range.
- Renal Impairment: No specific adjustment is established. Titrate to effect. Its inactive conjugates are cleared in urine.
- Hepatic Impairment: No specific adjustment is established.
- Obesity / Dosing Weight: The label gives no guidance. Use one institutional dosing weight per patient, and document it.
Field & Transport Considerations
- Scope: critical-care transport (CCT), RN and Paramedic crews usually carry on an infusion that the sending facility started. Who may start one varies by state and agency protocol.
- Storage & Stability: Keep premixed bags and vials at 20–25°C (68–77°F). Don't freeze them. Keep premixed bags in the overwrap until use, and away from vehicle heat. Diluted vial solutions must be used within 24 hr.
- Carried Concentration: Confirm 1, 2 or 4 mg/mL on the bag and in the pump library. Check that the bag says DOBUTamine, not DOPamine.
- Infusions in Transport: Give it a dedicated pump channel and line. Carry enough volume for the trip plus delays. Keep a vasopressor ready, because pressure can fall. Recheck the site after every move.
- Handoff Essentials: Give the start time, the current dose in mcg/kg/min and the dosing weight, the concentration, the last titration and the response (heart rate, rhythm, MAP, urine output, lactate), other vasoactive drugs, and the latest K⁺ and Mg²⁺.
Clinical Pearls
Inotrope, not pressor: Starting or raising dobutamine can drop the MAP. β₂-mediated and reflex vasodilation are the reason. If the patient is hypotensive, start norepinephrine first. Then add dobutamine for low output.
Sepsis: a trial, not a rescue: Think of dobutamine as a trial. SSC 2026 suggests adding it to norepinephrine, or using epinephrine alone, only for cardiac dysfunction with hypoperfusion that persists despite adequate volume and MAP. It suggests against levosimendan. In adults, stop it if lactate and capillary refill don't improve. Adult SSC no longer uses ScvO₂ targets. The children's guideline suggests ScvO₂ 70% or higher.
Dobutamine vs milrinone vs epinephrine:
- Dobutamine: β₁-predominant. Half-life about 2 min, so it is fast to titrate. Tachycardia and AF come with it.
- Milrinone: A PDE-3 inhibitor. It works despite β-blockade. It is renally cleared and longer acting, with more vasodilation.
- Epinephrine: α and β. It raises output and SVR, and it raises lactate.
- DOREMI (2021): No significant outcome difference between milrinone and dobutamine in cardiogenic shock.
- Septic shock with cardiac dysfunction: SSC 2026 suggests norepinephrine or epinephrine as the first-line vasopressor. Norepinephrine may be preferred with tachyarrhythmia.
Exam discriminator: "Cold and wet" heart failure with adequate blood pressure: inotrope (dobutamine) plus diuresis. "Cold and wet" with hypotension: norepinephrine first, then add the inotrope. New murmur and hypotension on dobutamine? Think outflow obstruction, and stop it.
AF with rapid response: Dobutamine speeds AV conduction. New AF on dobutamine: reduce the dose, correct K⁺ and Mg²⁺, and control the rate before escalating further.
Pharmacology
Mechanism of Action
- Racemic synthetic catecholamine: (+)-dobutamine is a potent β₁ and β₂ agonist. It binds α₁ receptors without activating them. (−)-dobutamine is an α₁ agonist.
- Net β₁ effect → more contractility and stroke volume → higher cardiac output, with a modest heart rate rise. It facilitates AV conduction.
- Vascular effects largely cancel → systemic vascular resistance usually falls as a reflex to the higher output. Blood pressure may rise, stay level or fall.
- Direct-acting: It does not release endogenous norepinephrine.
Pharmacokinetics
| Route | Onset | Peak | Duration |
|---|---|---|---|
| IV infusion | 1–2 min | Up to 10 min | About 10 min after stopping (about 5 half-lives) |
- Half-life: about 2 min. Plasma levels are proportional to the infusion rate.
- Metabolism: catechol-O-methyltransferase (COMT) methylation and conjugation.
- Active metabolites: none (3-O-methyldobutamine is inactive).
- Elimination: urine, as conjugates of dobutamine and 3-O-methyldobutamine.
- Tolerance: In the limited number of patients studied for 24, 48 and 72 hr, output stayed raised in some and drifted back toward baseline in others (label).
Names & Classification
- Generic Name
- Dobutamine hydrochloride (doses expressed as dobutamine base)
- Brand Names
- Dobutrex (discontinued); generic vials and premixed bags in D5W
- Pharmacologic Class
- Synthetic catecholamine; β₁-predominant adrenergic agonist
- Therapeutic Class
- Inotrope
- Controlled Substance
- Not controlled
- ISMP High-Alert
- Yes: ISMP high-alert medication (adrenergic agonists, IV)
- Look-Alike / Sound-Alike
- DOBUTamine / DOPamine (tall-man lettering pair)
References
- Hospira, Inc. (2025). Dobutamine in 5% dextrose injection, USP: prescribing information (revised 11/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9943a961-3b50-4847-8a84-d8414ce38daa
- Hospira, Inc. (2020). Dobutamine injection, USP (12.5 mg/mL concentrate): prescribing information (revised 11/2020; DailyMed version May 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89becb0c-da60-4f43-0a98-29ff7a9eca58
- Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895–e1032. https://doi.org/10.1161/CIR.0000000000001063
- Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., et al. (2026). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026. Intensive Care Medicine, 52(5), 863–936. https://doi.org/10.1007/s00134-026-08361-1 (co-published in Critical Care Medicine, doi:10.1097/CCM.0000000000007075)
- Weiss, S. L., Peters, M. J., Oczkowski, S. J. W., Belley-Cote, E., et al. (2026). Surviving Sepsis Campaign international guidelines for the management of sepsis and septic shock in children 2026. Pediatric Critical Care Medicine, 27(4), 379–434. https://doi.org/10.1097/PCC.0000000000003927 (co-published in Intensive Care Medicine, doi:10.1007/s00134-026-08360-2)
- Mathew, R., Di Santo, P., Jung, R. G., Marbach, J. A., et al. (2021). Milrinone as compared with dobutamine in the treatment of cardiogenic shock (DOREMI trial). New England Journal of Medicine, 385(6), 516–525. https://doi.org/10.1056/NEJMoa2026845
- Dubin, A., & Mugno, M. (2024). The effects of dobutamine in septic shock: An updated narrative review of clinical and experimental studies. Medicina, 60(5), 751. https://doi.org/10.3390/medicina60050751
- Sinha, S. S., Morrow, D. A., Kapur, N. K., Kataria, R., Roswell, R. O., et al. (2025). 2025 concise clinical guidance: An ACC expert consensus statement on the evaluation and management of cardiogenic shock. Journal of the American College of Cardiology, 85(16), 1618–1641. https://doi.org/10.1016/j.jacc.2025.02.018
- Baxter Healthcare Corporation (2023). Dobutamine hydrochloride in 5% dextrose injection: prescribing information (updated September 8, 2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead
- Ommen, S. R., Ho, C. Y., Asif, I. M., et al. (2024). 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy. Circulation, e1239–e1311. https://doi.org/10.1161/CIR.0000000000001250
- 2025 AHA Guidelines for CPR and ECC, Part 8: Pediatric Advanced Life Support (cardiogenic shock recommendation 2b). https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/pediatric-advanced-life-support
- National Association of State EMS Officials (2022). NASEMSO National Model EMS Clinical Guidelines, Version 3.0. https://nasemso.org/content.aspx?page_id=22&club_id=157064&module_id=701974
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.